Quantitative expression proteomics and phosphoproteomics profile of brain from PINK1 knockout mice: Insights into mechanisms of familial Parkinson's disease

Journal of Neurochemistry

Volumn 133, Issue 5, 2015, Pages 750-765

  Triplett, Judy C ^a   Zhang, Zhaoshu ^a   Sultana, Rukhsana ^a   Cai, Jian ^b   Klein, Jon B ^b   Büeler, Hansruedi ^c,d   Butterfield, David Allan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d HARBIN INSTITUTE OF TECHNOLOGY   (China)

Author keywords

Expression proteomics; Knockout mouse; Parkinson's disease; phosphoproteomics; PINK1

Indexed keywords

PHOSPHOPROTEOME; PROTEIN SERINE THREONINE KINASE; PROTEOME; PTEN INDUCED KINASE 1; UNCLASSIFIED DRUG; PEPTIDE; PHOSPHOPROTEIN; PROTEIN KINASE; PTEN-INDUCED PUTATIVE KINASE; TRYPSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN NERVE CELL; CELL STRUCTURE; CONTROLLED STUDY; ENERGY METABOLISM; FAMILIAL DISEASE; IMMUNOCHEMISTRY; INTRACELLULAR SIGNALING; KNOCKOUT MOUSE; MALE; MOLECULAR BIOLOGY; MOLECULAR PATHOLOGY; MOUSE; NERVE CELL PLASTICITY; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHOSPHOPROTEOMICS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ANALYSIS; WESTERN BLOTTING; WILD TYPE; ANIMAL; BRAIN CHEMISTRY; CHEMISTRY; GENETICS; IMMUNOPRECIPITATION; PROCEDURES;

ANIMALIA; MUS;

ANIMALS; BLOTTING, WESTERN; BRAIN CHEMISTRY; IMMUNOPRECIPITATION; MALE; MICE; MICE, KNOCKOUT; PARKINSON DISEASE; PEPTIDES; PHOSPHOPROTEINS; PROTEIN KINASES; PROTEOMICS; TRYPSIN;

EID: 84928010363     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13039     Document Type: Article

References (137)

1. Akundi R. S., Huang Z., Eason J., Pandya J. D., Zhi L., Cass W. A., and, Bueler H., (2011) Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice. PLoS ONE 6, e16038. doi: 10.1371/journal.pone.0016038.
2. Akundi R. S., Zhi L., and, Bueler H., (2012) PINK1 enhances insulin-like growth factor-1-dependent Akt signaling and protection against apoptosis. Neurobiol. Dis. 45, 469-478. doi: 10.1016/j.nbd.2011.08.034.
3. Akundi R. S., Zhi L., Sullivan P. G., and, Bueler H., (2013) Shared and cell type-specific mitochondrial defects and metabolic adaptations in primary cells from PINK1-deficient mice. Neurodegener. Dis. 12, 136-149. doi: 10.1159/000345689.
4. Altman J., (1969) Autoradiographic and histological studies of postnatal neurogenesis. IV. Cell proliferation and migration in the anterior forebrain, with special reference to persisting neurogenesis in the olfactory bulb. J. Comp. Neurol. 137, 433-457. doi: 10.1002/cne.901370404.
5. Alvarez-Erviti L., Rodriguez-Oroz M. C., Cooper J. M., Caballero C., Ferrer I., Obeso J. A., and, Schapira A. H., (2010) Chaperone-mediated autophagy markers in parkinson disease brains. Arch. Neurol. 67, 1464-1472. doi: 10.1001/archneurol.2010.198
6. Alzamora R., Thali R. F., Gong F., Smolak C., Li H., Baty C. J., and, Pastor-Soler N. M., (2010) PKA regulates vacuolar H + -ATPase localization and activity via direct phosphorylation of the a subunit in kidney cells. J. Biol. Chem. 285, 24676-24685. doi: 10.1074/jbc.M110.106278.
7. Amo T., Sato S., Saiki S., Wolf A. M., Toyomizu M., Gautier C. A., Shen J., Ohta S., and, Hattori N., (2011) Mitochondrial membrane potential decrease caused by loss of PINK1 is not due to proton leak, but to respiratory chain defects. Neurobiol. Dis. 41, 111-118. doi: http://dx.doi.org/10.1016/j.nbd.2010.08.027
8. Anderson J. P., Walker D. E., Goldstein J. M., de Laat R., Banducci K., Caccavello R. J., and, Chilcote T. J., (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739-29752. doi: 10.1074/jbc.M600933200.
9. Auluck P. K., Chan H. Y., Trojanowski J. Q., Lee V. M., and, Bonini N. M., (2002) Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295, 865-868. doi: 10.1126/science.1067389.
10. Barone P., (2010) Neurotransmission in Parkinson's disease: beyond dopamine. Eur. J. Neurol. 17, 364-376. doi: 10.1111/j.1468-1331.2009.02900.x.
11. Benaim G., and, Villalobo A., (2002) Phosphorylation of calmodulin. Functional implications. Eur. J. Biochem. 269, 3619-3631.
12. Beyenbach K. W., and, Wieczorek H., (2006) The V-type H+ ATPase: molecular structure and function, physiological roles and regulation. J. Exp. Biol. 209, 577-589. doi: 10.1242/jeb.02014.
13. Blachly-Dyson E., and, Forte M., (2001) VDAC Channels. IUBMB Life 52, 113-118. doi: 10.1080/15216540152845902.
14. Bomberger J. M., Parameswaran N., Hall C. S., Aiyar N., and, Spielman W. S., (2005) Novel function for receptor activity-modifying proteins (RAMPs) in post-endocytic receptor trafficking. J. Biol. Chem. 280, 9297-9307. doi: 10.1074/jbc.M413786200.
15. Bonifati V., (2012) Autosomal recessive parkinsonism. Parkinsonism Relat. Disord. 18 (Suppl 1), S4-S6. doi: 10.1016/S1353-8020(11)70004-9.
16. Bonifati V., Rohe C. F., Breedveld G. J., et al,.; Italian Parkinson Genetics Network (2005) Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 65, 87-95. doi: 10.1212/01.wnl.0000167546.39375.82
17. Braak H., Tredici K. D., Rüb U., de Vos R. A. I., Jansen Steur E. N. H., and, Braak E., (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211. doi: http://dx.doi.org/10.1016/S0197-4580(02)00065-9
18. Bueler H., (2009) Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp. Neurol. 218, 235-246. doi: 10.1016/j.expneurol.2009.03.006.
19. Bukhatwa S., Zeng B.-Y., Rose S., and, Jenner P., (2010) A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Brain Res. 1326, 174-183. doi: http://dx.doi.org/10.1016/j.brainres.2010.02.045
20. Butterfield D. A., and, Lange M. L., (2009) Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J. Neurochem. 111, 915-933. doi: 10.1111/j.1471-4159.2009.06397.x.
21. Charrier E., Reibel S., Rogemond V., Aguera M., Thomasset N., and, Honnorat J., (2003) Collapsin response mediator proteins (CRMPs): involvement in nervous system development and adult neurodegenerative disorders. Mol. Neurobiol. 28, 51-64. doi: 10.1385/MN:28:1:51.
22. Chaudhuri K. R., Healy D. G., and, Schapira A. H.,; National Institute for Clinical Exellence (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 5, 235-245. doi: 10.1016/S1474-4422(06)70373-8
23. Cheng A., Hou Y., and, Mattson M. P., (2010) Mitochondria and neuroplasticity. ASN Neuro 2, e00045. doi: 10.1042/an20100019.
24. Choi I., Kim J., Jeong H. K., Kim B., Jou I., Park S. M., and, Joe E. H., (2013) PINK1 deficiency attenuates astrocyte proliferation through mitochondrial dysfunction, reduced AKT and increased p38 MAPK activation, and downregulation of EGFR. Glia 61, 800-812. doi: 10.1002/glia.22475.
25. Davies K. J. A., (2001) Degradation of oxidized proteins by the 20S proteasome. Biochimie 83, 301-310. doi: http://dx.doi.org/10.1016/S0300-9084(01)01250-0
26. De Winter F., Vo T., Stam F. J., Wisman L. A., Bar P. R., Niclou S. P., and, Verhaagen J., (2006) The expression of the chemorepellent Semaphorin 3A is selectively induced in terminal Schwann cells of a subset of neuromuscular synapses that display limited anatomical plasticity and enhanced vulnerability in motor neuron disease. Mol. Cell Neurosci. 32, 102-117. doi: 10.1016/j.mcn.2006.03.002.
27. Deas E., Plun-Favreau H., Gandhi S., Desmond H., Kjaer S., Loh S. H., and, Wood N. W., (2011) PINK1 cleavage at position A103 by the mitochondrial protease PARL. Hum. Mol. Genet. 20, 867-879. doi: 10.1093/hmg/ddq526.
28. Dehay B., Martinez-Vicente M., Caldwell G. A., Caldwell K. A., Yue Z., Cookson M. R., and, Bezard E., (2013) Lysosomal impairment in Parkinson's disease. Mov. Disord. 28, 725-732. doi: 10.1002/mds.25462.
29. Dekker F. J., Rocks O., Vartak N., Menninger S., Hedberg C., Balamurugan R., and, Waldmann H., (2010) Small-molecule inhibition of APT1 affects Ras localization and signaling. Nat. Chem. Biol. 6, 449-456. doi: 10.1038/nchembio.362.
30. DeLorenzo R. J., (1980) Role of calmodulin in neurotransmitter release and synaptic function. Ann. N. Y. Acad. Sci. 356, 92-109.
31. Di Domenico F., Sultana R., Barone E., Perluigi M., Cini C., Mancuso C., and, Butterfield D. A., (2011) Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects. J. Proteomics. 74, 1091-1103. doi: 10.1016/j.jprot.2011.03.033.
32. Di Domenico F., Sultana R., Ferree A., Smith K., Barone E., Perluigi M., and, Butterfield D. A., (2012) Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease. Antioxid. Redox Signal. 17, 1490-1506. doi: 10.1089/ars.2011.4312.
33. Diedrich M., Kitada T., Nebrich G., Koppelstaetter A., Shen J., Zabel C., and, Mao L., (2011) Brain region specific mitophagy capacity could contribute to selective neuronal vulnerability in Parkinson's disease. Proteome Sci. 9, 59. doi: 10.1186/1477-5956-9-59.
34. Dixit A., Srivastava G., Verma D., Mishra M., Singh P. K., Prakash O., and, Singh M. P., (2013) Minocycline, levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson's disease. Biochim. Biophys. Acta 1832, 1227-1240. doi: 10.1016/j.bbadis.2013.03.019.
35. Dong Z., Wolfer D. P., Lipp H. P., and, Bueler H., (2005) Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. Mol. Ther. 11, 80-88. doi: 10.1016/j.ymthe.2004.09.007.
36. Dzamko N., Zhou J., Huang Y., and, Halliday G. M., (2014) Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis. Front. Mol. Neurosci. 7, 57. doi: 10.3389/fnmol.2014.00057.
37. Ebrahimi-Fakhari D., Wahlster L., and, McLean P., (2012) Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathol. 124, 153-172. doi: 10.1007/s00401-012-1004-6.
38. Eriksson P. S., Perfilieva E., Bjork-Eriksson T., Alborn A. M., Nordborg C., Peterson D. A., and, Gage F. H., (1998) Neurogenesis in the adult human hippocampus. Nat. Med. 4, 1313-1317. doi: 10.1038/3305.
39. Esposito G., Ana Clara F., and, Verstreken P., (2012) Synaptic vesicle trafficking and Parkinson's disease. Dev. Neurobiol. 72, 134-144. doi: 10.1002/dneu.20916.
40. Exner N., Treske B., Paquet D., et al,. (2007) Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J. Neurosci. 27, 12413-12418. doi: 10.1523/JNEUROSCI.0719-07.2007.
41. Fedorowicz M. A., de Vries-Schneider R. L., Rub C., Becker D., Huang Y., Zhou C., Alessi Wolken D. M., Voos W., Liu Y., and, Przedborski S., (2014) Cytosolic cleaved PINK1 represses Parkin translocation to mitochondria and mitophagy. EMBO Rep. 15, 86-93. doi: 10.1002/embr.201337294
42. Ferrer I., Perez E., Dalfo E., and, Barrachina M., (2007) Abnormal levels of prohibitin and ATP synthase in the substantia nigra and frontal cortex in Parkinson's disease. Neurosci. Lett. 415, 205-209. doi: 10.1016/j.neulet.2007.01.026.
43. Foote M., and, Zhou Y., (2012) 14-3-3 proteins in neurological disorders. Int. J. Biochem. Mol. Biol. 3, 152-164.
44. Fu H., Subramanian R. R., and, Masters S. C., (2000) 14-3-3 proteins: structure, function, and regulation. Annu. Rev. Pharmacol. Toxicol. 40, 617-647. doi: 10.1146/annurev.pharmtox.40.1.617.
45. Fuchs E., and, Cleveland D. W., (1998) A structural scaffolding of intermediate filaments in health and disease. Science 279, 514-519.
46. Gasser T., Hardy J., and, Mizuno Y., (2011) Milestones in PD genetics. Mov. Disord. 26, 1042-1048. doi: 10.1002/mds.23637.
47. Gautier C. A., Kitada T., and, Shen J., (2008) Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc. Natl Acad. Sci. USA 105, 11364-11369. doi: 10.1073/pnas.0802076105.
48. Gautier C. A., Giaime E., Caballero E., Nunez L., Song Z., Chan D., Villalobos C., and, Shen J., (2012) Regulation of mitochondrial permeability transition pore by PINK1. Mol. Neurodegener. 7, 22. doi: 10.1186/1750-1326-7-22.
49. Glasl L., Kloos K., Giesert F., et al,. (2012) Pink1-deficiency in mice impairs gait, olfaction and serotonergic innervation of the olfactory bulb. Exp. Neurol. 235, 214-227. doi: 10.1016/j.expneurol.2012.01.002.
50. Gournier H., Goley E. D., Niederstrasser H., Trinh T., and, Welch M. D., (2001) Reconstitution of human Arp2/3 complex reveals critical roles of individual subunits in complex structure and activity. Mol. Cell 8, 1041-1052. doi: http://dx.doi.org/10.1016/S1097-2765(01)00393-8
51. Guibinga G. H., Hsu S., and, Friedmann T., (2010) Deficiency of the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase (HPRT) dysregulates neurogenesis. Mol. Ther. 18, 54-62. doi: 10.1038/mt.2009.178.
52. Hafner A., Glavan G., Obermajer N., Živin M., Schliebs R., and, Kos J., (2013) Neuroprotective role of γ-enolase in microglia in a mouse model of Alzheimer's disease is regulated by cathepsin X. Aging Cell, 12, 604-614. doi: 10.1111/acel.12093.
53. Haque M. E., Thomas K. J., D'Souza C., Callaghan S., Kitada T., Slack R. S., Fraser P., Cookson M. R., Tandon A., and, Park D. S., (2008) Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proc. Natl Acad. Sci. USA 105, 1716-1721. doi: 10.1073/pnas.0705363105.
54. Hauser D. N., and, Hastings T. G., (2013) Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol. Dis. 51, 35-42. doi: 10.1016/j.nbd.2012.10.011.
55. Heeman B., Van den Haute C., Aelvoet S. A., et al,. (2011) Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance. J. Cell Sci. 124, 1115-1125. doi: 10.1242/jcs.078303.
56. Henchcliffe C., and, Beal M. F., (2008) Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 4, 600-609. doi: 10.1038/ncpneuro0924.
57. Hensley K., Venkova K., Christov A., Gunning W., and, Park J., (2011) Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications. Mol. Neurobiol. 43, 180-191. doi: 10.1007/s12035-011-8166-4.
58. Hill W. D., Arai M., Cohen J. A., and, Trojanowski J. Q., (1993) Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons. J. Comp. Neurol. 329, 328-336. doi: 10.1002/cne.903290304.
59. Iketani M., Iizuka A., Sengoku K., et al,. (2013) Regulation of neurite outgrowth mediated by localized phosphorylation of protein translational factor eEF2 in growth cones. Dev. Neurobiol. 73, 230-246. doi: 10.1002/dneu.22058.
60. Jankovic J., (2008) Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79, 368-376. doi: 10.1136/jnnp.2007.131045.
61. Jenner P., (2003) Oxidative stress in Parkinson's disease. Ann. Neurol. 53 (Suppl 3), S26-S36; discussion S36-28. doi: 10.1002/ana.10483
62. Jin S. M., and, Youle R. J., (2012) PINK1- and Parkin-mediated mitophagy at a glance. J. Cell Sci. 125, 795-799. doi: 10.1242/jcs.093849.
63. Kazlauskaite A., Kondapalli C., Gourlay R., Campbell D. G., Ritorto M. S., Hofmann K., Alessi D. R., Knebel A., Trost M., and, Muqit M. M., (2014) Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65. Biochem. J. 460, 127-139. doi: 10.1042/BJ20140334.
64. Khanna R., Wilson S. M., Brittain J. M., Weimer J., Sultana R., Butterfield A., and, Hensley K., (2012) Opening Pandora's jar: a primer on the putative roles of CRMP2 in a panoply of neurodegenerative, sensory and motor neuron, and central disorders. Future Neurol. 7, 749-771. doi: 10.2217/FNL.12.68.
65. Kingsbury A. E., Cooper M., Schapira A. H., and, Foster O. J., (2001) Metabolic enzyme expression in dopaminergic neurons in Parkinson's disease: an in situ hybridization study. Ann. Neurol. 50, 142-149.
66. Koh H., and, Chung J., (2012) PINK1 as a molecular checkpoint in the maintenance of mitochondrial function and integrity. Mol. Cells 34, 7-13. doi: 10.1007/s10059-012-0100-8.
67. Kong E., Peng S., Chandra G., Sarkar C., Zhang Z., Bagh M. B., and, Mukherjee A. B., (2013) Dynamic palmitoylation links cytosol-membrane shuttling of acyl-protein thioesterase-1 and acyl-protein thioesterase-2 with that of proto-oncogene H-ras product and growth-associated protein-43. J. Biol. Chem. 288, 9112-9125. doi: 10.1074/jbc.M112.421073.
68. Lang A. E., (2011) A critical appraisal of the premotor symptoms of Parkinson's disease: potential usefulness in early diagnosis and design of neuroprotective trials. Mov. Disord. 26, 775-783. doi: 10.1002/mds.23609.
69. Lang K., Schmid F. X., and, Fischer G., (1987) Catalysis of protein folding by prolyl isomerase. Nature 329, 268-270. doi: 10.1038/329268a0.
70. Lee S. M., Koh H.-J., Park D.-C., Song B. J., Huh T.-L., and, Park J.-W., (2002) Cytosolic NADP+-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic. Biol. Med. 32, 1185-1196. doi: http://dx.doi.org/10.1016/S0891-5849(02)00815-8
71. Lenzi P., Marongiu R., Falleni A., Gelmetti V., Busceti C. L., Michiorri S., Valente E. M., and, Fornai F., (2012) A subcellular analysis of genetic modulation of PINK1 on mitochondrial alterations, autophagy and cell death. Arch. Ital. Biol. 150, 194-217. doi: 10.4449/aib.v150i2/3.1417.
72. Liang C. L., Wang T. T., Luby-Phelps K., and, German D. C., (2007) Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease. Exp. Neurol. 203, 370-380. doi: 10.1016/j.expneurol.2006.08.015.
73. Lim K. L., (2007) Ubiquitin-proteasome system dysfunction in Parkinson's disease: current evidence and controversies. Expert Rev. Proteomics 4, 769-781. doi: 10.1586/14789450.4.6.769.
74. Lin W., and, Kang U. J., (2008) Characterization of PINK1 processing, stability, and subcellular localization. J. Neurochem. 106, 464-474. doi: 10.1111/j.1471-4159.2008.05398.x.
75. Lin R. C., and, Scheller R. H., (2000) Mechanisms of synaptic vesicle exocytosis. Annu. Rev. Cell Dev. Biol. 16, 19-49. doi: 10.1146/annurev.cellbio.16.1.19.
76. Liu S., and, Lu B., (2010) Reduction of protein translation and activation of autophagy protect against PINK1 pathogenesis in Drosophila melanogaster. PLoS Genet. 6, e1001237. doi: 10.1371/journal.pgen.1001237.
77. LiuQ Q., Xie F., Alvarado-Diaz A., Smith M. A., Moreira P. I., Zhu X., and, Perry G., (2011a) Neurofilamentopathy in neurodegenerative diseases. Open Neurol. J. 5, 58-62. doi: 10.2174/1874205X01105010058.
78. Liu W., Acin-Perez R., Geghman K. D., Manfredi G., Lu B., and, Li C., (2011b) Pink1 regulates the oxidative phosphorylation machinery via mitochondrial fission. Proc. Natl Acad. Sci. USA 108, 12920-12924. doi: 10.1073/pnas.1107332108.
79. Mallajosyula J. K., Chinta S. J., Rajagopalan S., Nicholls D. G., and, Andersen J. K., (2009) Metabolic control analysis in a cellular model of elevated MAO-B: relevance to Parkinson's disease. Neurotox. Res. 16, 186-193. doi: 10.1007/s12640-009-9032-2.
80. Martins-Branco D., Esteves A. R., Santos D., Arduino D. M., Swerdlow R. H., Oliveira C. R., Januario C., and, Cardoso S. M., (2012) Ubiquitin proteasome system in Parkinson's disease: a keeper or a witness? Exp. Neurol. 238, 89-99. doi: http://dx.doi.org/10.1016/j.expneurol.2012.08.008
81. Matsuda N., Sato S., Shiba K., et al,. (2010) PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J. Cell Biol. 189, 211-221. doi: 10.1083/jcb.200910140.
82. Meimaridou E., Gooljar S. B., and, Chapple J. P., (2009) From hatching to dispatching: the multiple cellular roles of the Hsp70 molecular chaperone machinery. J. Mol. Endocrinol. 42, 1-9. doi: 10.1677/jme-08-0116.
83. Meissner C., Lorenz H., Weihofen A., Selkoe D. J., and, Lemberg M. K., (2011) The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking. J. Neurochem. 117, 856-867. doi: 10.1111/j.1471-4159.2011.07253.x.
84. Micheli V., Camici M., Tozzi M. G., Ipata P. L., Sestini S., Bertelli M., and, Pompucci G., (2011) Neurological disorders of purine and pyrimidine metabolism. Curr. Top. Med. Chem. 11, 923-947.
85. Miura T., Nishinaka T., and, Terada T., (2008) Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1. Mol. Cell. Biochem. 315, 113-121. doi: 10.1007/s11010-008-9794-5.
86. Morais V. A., Verstreken P., Roethig A., et al,. (2009) Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function. EMBO Mol. Med. 1, 99-111. doi: 10.1002/emmm.200900006.
87. Morais V. A., Haddad D., Craessaerts K., et al,. (2014) PINK1 loss-of-function mutations affect mitochondrial complex I activity via NdufA10 ubiquinone uncoupling. Science 344, 203-207. doi: 10.1126/science.1249161.
88. Mukai H., Toshimori M., Shibata H., Kitagawa M., Shimakawa M., Miyahara M., Sunakawa H., and, Ono Y., (1996) PKN associates and phosphorylates the head-rod domain of neurofilament protein. J. Biol. Chem. 271, 9816-9822.
89. Murata H., Sakaguchi M., Jin Y., Sakaguchi Y., Futami J., Yamada H., Kataoka K., and, Huh N. H., (2011) A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK/PINK1: activation of AKT via mTORC2. J. Biol. Chem. 286, 7182-7189. doi: 10.1074/jbc.M110.179390.
90. Nairn A. C., and, Palfrey H. C., (1987) Identification of the major Mr 100,000 substrate for calmodulin-dependent protein kinase III in mammalian cells as elongation factor-2. J. Biol. Chem. 262, 17299-17303.
91. Narendra D. P., Jin S. M., Tanaka A., Suen D. F., Gautier C. A., Shen J., Cookson M. R., and, Youle R. J., (2010) PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 8, e1000298. doi: 10.1371/journal.pbio.1000298.
92. Nemani V. M., Lu W., Berge V., Nakamura K., Onoa B., Lee M. K., Chaudhry F. A., Nicoll R. A., and, Edwards R. H., (2010) Increased expression of a-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65, 66-79. doi: http://dx.doi.org/10.1016/j.neuron.2009.12.023
93. Neuwald A. F., (1999) The hexamerization domain of N-ethylmaleimide-sensitive factor: structural clues to chaperone function. Structure 7, R19-R23.
94. van Oosten-Hawle P., and, Morimoto R. I., (2014) Organismal proteostasis: role of cell-nonautonomous regulation and transcellular chaperone signaling. Genes Dev. 28, 1533-1543. doi: 10.1101/gad.241125.114.
95. Oppermann U., (2007) Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. Annu. Rev. Pharmacol. Toxicol. 47, 293-322. doi: 10.1146/annurev.pharmtox.47.120505.105316.
96. Pan T., Kondo S., Le W., and, Jankovic J., (2008) The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 131, 1969-1978. doi: 10.1093/brain/awm318.
97. Park J., Lee S. B., Lee S., et al,. (2006) Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441, 1157-1161. doi: 10.1038/nature04788.
98. Patt S., Gertz H. J., Gerhard L., and, Cervos-Navarro J., (1991) Pathological changes in dendrites of substantia nigra neurons in Parkinson's disease: a Golgi study. Histol. Histopathol. 6, 373-380.
99. Pilsl A., and, Winklhofer K. F., (2012) Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease. Acta Neuropathol. 123, 173-188. doi: 10.1007/s00401-011-0902-3.
100. Redeker V., Pemberton S., Bienvenut W., Bousset L., and, Melki R., (2012) Identification of protein interfaces between alpha-synuclein, the principal component of Lewy bodies in Parkinson disease, and the molecular chaperones human Hsc70 and the yeast Ssa1p. J. Biol. Chem. 287, 32630-32639. doi: 10.1074/jbc.M112.387530.
101. Ren T. J., Qiang R., Jiang Z. L., Wang G. H., Sun L., Jiang R., Zhao G. W., and, Han L. Y., (2013) Improvement in regional CBF by L-serine contributes to its neuroprotective effect in rats after focal cerebral ischemia. PLoS ONE 8, e67044. doi: 10.1371/journal.pone.0067044
102. Requejo-Aguilar R., Lopez-Fabuel I., Fernandez E., Martins L. M., Almeida A., and, Bolanos J. P., (2014) PINK1 deficiency sustains cell proliferation by reprogramming glucose metabolism through HIF1. Nat. Commun. 5, 4514. doi: 10.1038/ncomms5514.
103. Robinson R. A., Joshi G., Huang Q., Sultana R., Baker A. S., Cai J., Pierce W., St Clair D. K., Markesbery W. R., and, Butterfield D. A., (2011) Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid beta-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's disease. Proteomics 11, 4243-4256. doi: 10.1002/pmic.201000523.
104. Samann J., Hegermann J., von Gromoff E., Eimer S., Baumeister R., and, Schmidt E., (2009) Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J. Biol. Chem. 284, 16482-16491. doi: 10.1074/jbc.M808255200.
105. Sculley D. G., Dawson P. A., Emmerson B. T., and, Gordon R. B., (1992) A review of the molecular basis of hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency. Hum. Genet. 90, 195-207.
106. Shinkai-Ouchi F., Yamakawa Y., Hara H., Tobiume M., Nishijima M., Hanada K., and, Hagiwara K., (2010) Identification and structural analysis of C-terminally truncated collapsin response mediator protein-2 in a murine model of prion diseases. Proteome Sci. 8, 53. doi: 10.1186/1477-5956-8-53.
107. Shoshan-Barmatz V., and, Gincel D., (2003) The voltage-dependent anion channel. Cell Biochem. Biophys. 39, 279-292. doi: 10.1385/cbb:39:3:279.
108. Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J., and, Klenk D. C., (1985) Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85.
109. Spillane M., Ketschek A., Donnelly C. J., Pacheco A., Twiss J. L., and, Gallo G., (2012) Nerve growth factor-induced formation of axonal filopodia and collateral branches involves the intra-axonal synthesis of regulators of the actin-nucleating Arp2/3 complex. J. Neurosci. 32, 17671-17689. doi: 10.1523/JNEUROSCI.1079-12.2012.
110. Sultana R., Boyd-Kimball D., Poon H. F., Cai J., Pierce W. M., Klein J. B., Merchant M., Markesbery W. R., and, Butterfield D. A., (2006) Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol. Aging 27, 1564-1576. doi: 10.1016/j.neurobiolaging.2005.09.021.
111. Sultana R., Boyd-Kimball D., Cai J., Pierce W. M., Klein J. B., Merchant M., and, Butterfield D. A., (2007) Proteomics analysis of the Alzheimer's disease hippocampal proteome. J. Alzheimers Dis. 11, 153-164.
112. Sun Y., Vashisht A. A., Tchieu J., Wohlschlegel J. A., and, Dreier L., (2012) Voltage-dependent anion channels (VDACs) recruit Parkin to defective mitochondria to promote mitochondrial autophagy. J. Biol. Chem. 287, 40652-40660. doi: 10.1074/jbc.M112.419721.
113. Surmeier D. J., Guzman J. N., Sanchez-Padilla J., and, Schumacker P. T., (2011) The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neuroscience 198, 221-231. doi: 10.1016/j.neuroscience.2011.08.045.
114. Sutton M. A., Taylor A. M., Ito H. T., Pham A., and, Schuman E. M., (2007) Postsynaptic decoding of neural activity: eEF2 as a biochemical sensor coupling miniature synaptic transmission to local protein synthesis. Neuron 55, 648-661. doi: http://dx.doi.org/10.1016/j.neuron.2007.07.030
115. Takahashi N., Hayano T., and, Suzuki M., (1989) Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature 337, 473-475. doi: 10.1038/337473a0.
116. Tan M., Ma S., Huang Q., Hu K., Song B., and, Li M., (2013) GSK-3alpha/beta-mediated phosphorylation of CRMP-2 regulates activity-dependent dendritic growth. J. Neurochem. 125, 685-697. doi: 10.1111/jnc.12230.
117. Tansey M. G., and, Goldberg M. S., (2010) Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 37, 510-518. doi: 10.1016/j.nbd.2009.11.004.
118. Theiss A. L., and, Sitaraman S. V., (2011) The role and therapeutic potential of prohibitin in disease. Biochim. Biophys. Acta 1813, 1137-1143. doi: 10.1016/j.bbamcr.2011.01.033.
119. Thongboonkerd V., McLeish K. R., Arthur J. M., and, Klein J. B., (2002) Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int. 62, 1461-1469. doi: 10.1111/j.1523-1755.2002.kid565.x.
120. Tian L., McClafferty H., Knaus H. G., Ruth P., and, Shipston M. J., (2012) Distinct acyl protein transferases and thioesterases control surface expression of calcium-activated potassium channels. J. Biol. Chem. 287, 14718-14725. doi: 10.1074/jbc.M111.335547.
121. Tufi R., Gandhi S., de Castro I. P., et al,. (2014) Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson's disease. Nat. Cell Biol. 16, 157-166. doi: 10.1038/ncb2901.
122. Twelves D., Perkins K. S. M., and, Counsell C., (2003) Systematic review of incidence studies of Parkinson's disease. Mov. Disord. 18, 19-31. doi: 10.1002/mds.10305.
123. Valente E. M., Abou-Sleiman P. M., Caputo V., et al,. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160. doi: 10.1126/science.1096284.
124. Van Laar V. S., and, Berman S. B., (2013) The interplay of neuronal mitochondrial dynamics and bioenergetics: implications for Parkinson's disease. Neurobiol. Dis. 51, 43-55. doi: 10.1016/j.nbd.2012.05.015.
125. Varcin M., Bentea E., Michotte Y., and, Sarre S., (2012) Oxidative stress in genetic mouse models of Parkinson's disease. Oxid. Med. Cell. Longev. 2012, 624925. doi: 10.1155/2012/624925.
126. Whiteheart S. W., Rossnagel K., Buhrow S. A., Brunner M., Jaenicke R., and, Rothman J. E., (1994) N-ethylmaleimide-sensitive fusion protein: a trimeric ATPase whose hydrolysis of ATP is required for membrane fusion. J. Cell Biol. 126, 945-954.
127. Whiteheart S. W., Schraw T., and, Matveeva E. A., (2001) N-Ethylmaleimide sensitive factor NSF structure and function. Int. Rev. Cytol. 207, 71-112.
128. Xia Z., and, Storm D. R., (2005) The role of calmodulin as a signal integrator for synaptic plasticity. Nat. Rev. Neurosci. 6, 267-276. doi: 10.1038/nrn1647.
129. Xu X., Zhao J., Xu Z., Peng B., Huang Q., Arnold E., and, Ding J., (2004) Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J. Biol. Chem. 279, 33946-33957. doi: 10.1074/jbc.M404298200.
130. Yamano K., and, Youle R. J., (2013) PINK1 is degraded through the N-end rule pathway. Autophagy 9, 1758-1769. doi: 10.4161/auto.24633.
131. Yang E. S., and, Park J. W., (2011) Knockdown of cytosolic NADP(+) -dependent isocitrate dehydrogenase enhances MPP(+) -induced oxidative injury in PC12 cells. BMB Rep. 44, 312-316. doi: 10.5483/BMBRep.2011.44.5.312
132. Yao Z., Gandhi S., Burchell V. S., Plun-Favreau H., Wood N. W., and, Abramov A. Y., (2012) Cell metabolism affects selective vulnerability in PINK1-associated Parkinson's disease. J. Cell Sci. doi: 10.1242/jcs.088260.
133. Yuan X. L., Guo J. F., Shi Z. H., Xiao Z. Q., Yan X. X., Zhao B. L., and, Tang B. S., (2010) R492X mutation in PTEN-induced putative kinase 1 induced cellular mitochondrial dysfunction and oxidative stress. Brain Res. 1351, 229-237. doi: 10.1016/j.brainres.2010.06.005.
134. Zhou T. B., and, Qin Y. H., (2013) Signaling pathways of prohibitin and its role in diseases. J. Recept. Signal Transduct. Res. 33, 28-36. doi: 10.3109/10799893.2012.752006.
135. Zhou Z. D., Refai F. S., Xie S. P., Ng S. H., Chan C. H., Ho P. G., Zhang X. D., Lim T. M., and, Tan E. K., (2014) Mutant PINK1 upregulates tyrosine hydroxylase and dopamine levels, leading to vulnerability of dopaminergic neurons. Free Radic. Biol. Med. 68, 220-233. doi: 10.1016/j.freeradbiomed.2013.12.015.
136. Zhu J. H., Kulich S. M., Oury T. D., and, Chu C. T., (2002) Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases. Am. J. Pathol. 161, 2087-2098. doi: 10.1016/S0002-9440(10)64487-2.
137. Zhu J. H., Guo F., Shelburne J., Watkins S., and, Chu C. T., (2003) Localization of phosphorylated ERK/MAP kinases to mitochondria and autophagosomes in Lewy body diseases. Brain Pathol. 13, 473-481.